A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
The aim of this phase II study was to examine the efficacy of combination chemotherapy comprising epirubicin, cisplatin and protracted infusion 5-fluorouracil in patients with metastatic prostate cancer. 21 patients were treated, of whom 9 (43%) responded for a minimum of 7 months. Continuation of previously effective second-line hormone therapies appeared to be a determinant of response; only 1 of 6 patients responded after its discontinuation. In a further 3 patients, response was only seen after re-introduction of previously effective hormone treatments. In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions.
Chao
D
D
Department of Oncology, U.C.L. Medical School, Middlesex Hospital, London, U.K.
von Schlippe
M
M
Harland
S J
SJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000473:pathology*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil